| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Demethylase; DMTase; Mbd2; MBD2a;;MBD2 |
| WB Predicted band size | Calculated MW: 43 kDa ; Observed MW: 43,32,29 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human MBD2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于MBD2抗体的3篇参考文献及其摘要概括：
---
### 1. **"MBD2 is a transcriptional co-repressor involved in gene silencing through DNA methylation"**
**作者**: Wade, P.A., Jones, P.L., Vermaak, D., Wolffe, A.P.
**摘要**: 该研究利用特异性MBD2抗体，通过染色质免疫沉淀(ChIP)和蛋白质组学分析，揭示了MBD2在甲基化DNA依赖性基因沉默中的作用。研究发现MBD2与组蛋白去乙酰化酶复合物(如NuRD)相互作用，证实其作为转录抑制因子的功能。
---
### 2. **"MBD2 suppresses epithelial-mesenchymal transition in lung cancer by targeting miR-21-mediated PDCD4"**
**作者**: Zhang, Y., Wang, X., Han, L. et al.
**摘要**: 本研究通过免疫组化(使用MBD2抗体)和分子实验，发现MBD2在肺癌中通过抑制miR-21表达来上调PDCD4蛋白，从而阻碍上皮间质转化(EMT)。结果提示MBD2低表达与肺癌患者不良预后相关。
---
### 3. **"Dynamic regulation of DNA methylation and gene expression during T cell differentiation"**
**作者**: Hutchins, A.P., Takahashi, Y., Miranda-Saavedra, D.
**摘要**: 研究利用MBD2抗体进行Western blot和ChIP-seq分析，探讨T细胞分化中DNA甲基化动态调控。发现MBD2与甲基化DNA结合后招募抑制复合物，调控关键转录因子(如Foxp3)的表达，影响T细胞功能。
---
**备注**：若需更多文献，可进一步筛选侧重抗体开发或验证的研究(如商业抗体说明书或方法学论文)。
The MBD2 (Methyl-CpG Binding Domain Protein 2) antibody is a crucial tool for studying epigenetic regulation mediated by DNA methylation. MBD2. a member of the methyl-CpG-binding domain protein family, binds to methylated DNA and recruits chromatin-remodeling complexes like MeCP1 and NuRD, facilitating gene silencing through histone deacetylation and chromatin compaction. It plays roles in X-chromosome inactivation, genomic imprinting, and maintaining heterochromatin stability. Dysregulation of MBD2 is implicated in cancers, neurodevelopmental disorders, and autoimmune diseases, with overexpression observed in certain tumors, linking it to oncogenic pathways and immune evasion.
MBD2 antibodies enable the detection and quantification of MBD2 protein levels in tissues or cells via techniques like Western blotting, immunohistochemistry, and immunofluorescence. They are also used in chromatin immunoprecipitation (ChIP) to map MBD2-DNA interactions, aiding research on methylation-dependent gene regulation. Validated for specificity, these antibodies help explore MBD2's role in cellular differentiation, tumor progression, and therapeutic responses. Their applications span cancer epigenetics, stem cell biology, and developmental studies, providing insights into disease mechanisms and potential biomarkers. Commercial MBD2 antibodies are typically raised against conserved regions (e.g., the methyl-binding domain) and are available in monoclonal or polyclonal formats.
×
